West Pharmaceutical Services explosion

Thermo Fisher Scientific Confirms Detection of SARS-CoV-2 in Samples Containing the Omicron Variant with its TaqPath COVID-19 Tests

Retrieved on: 
Monday, November 29, 2021
Thermo Fisher Scientific, Invitrogen, GISAID, Applied Biosystems, World Health Organization, Fisher Scientific, Mindful Scientific Inc., UKZN, PCR, NYSE, WHO, Center, World, Responsibility, Alpha, Severe acute respiratory syndrome coronavirus 2, Virus, TMO, West Pharmaceutical Services explosion, Laboratory, Vaccine, Stellenbosch University, COVID-19, Research, Risk, Mutation, Infection, Polymerase chain reaction, N, FDA, Patheon, Science, EUA, Travel, Animal

The Omicron variant, which was designated a " variant of concern " by the World Health Organization (WHO), has more than 30 mutations in the spike protein alone.

Key Points: 
  • The Omicron variant, which was designated a " variant of concern " by the World Health Organization (WHO), has more than 30 mutations in the spike protein alone.
  • The Omicron variant has been found to include the 69-70del mutation of the S gene, first identified as a mutation in the Alpha variant.
  • In addition to the original TaqPath COVID-19 tests, Thermo Fisher has developed the TaqPath COVID-19 2.0 tests with an advanced assay design to compensate for emerging mutations.
  • Specific genotyping assays to detect the Omicron variant are being developed for Thermo Fisher's TaqMan Mutation Panel .

Thermo Fisher Scientific Advances Proteomics Through Select Collaborations and New Analytical Instrument Solutions

Retrieved on: 
Monday, November 15, 2021
UHPLC, Efficiency, LC, B cell, Litre, Biomarker, Science, Mindful Scientific Inc., Fisher Scientific, HUPO, West Pharmaceutical Services explosion, PAC, SAN, Thermo Fisher Scientific, Technology, Proteomics, Research, Software, Invitrogen, Human Proteome Organization, Workflow, Mass spectrometry, Protein, LC-MS, Acquisition, Biotechnology, Solution, Co-marketing, Laboratory, Patheon, Applied Biosystems, MS, TMT, Fine chemical

"Proteomics research has the potential to expand our scientific understanding and uncover new biomarkers to meet unmet medical needs," said Andreas Huhmer, senior director, life sciences research omics marketing, Thermo Fisher Scientific.

Key Points: 
  • "Proteomics research has the potential to expand our scientific understanding and uncover new biomarkers to meet unmet medical needs," said Andreas Huhmer, senior director, life sciences research omics marketing, Thermo Fisher Scientific.
  • The Thermo Scientific Vanquish Neo Ultra-High Performance Liquid Chromatography (UHPLC) System complements high-resolution Thermo Scientific Orbitrap mass spectrometry for proteomics analyses, minimizing sample loss and delivering the highest quality of data.
  • A co-marketing agreement between Thermo Fisher and Cellenion, experts in single-cell sample preparation solutions, will deliver a full workflow, from sample to results, for scientists performing single-cell proteomics analysis.
  • Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $35 billion.

Thermo Fisher Scientific Selects Mebane, N.C. as Site for New Manufacturing Facility

Retrieved on: 
Friday, November 12, 2021
Thermo, Economic development, Science, Mindful Scientific Inc., Fisher Scientific, Product life-cycle theory, West Pharmaceutical Services explosion, Government, Thermo Fisher Scientific, Engineering, COVID, Commissioner, Orange County Board of Supervisors, Research, Workforce, High Point, U.S. Department of Defense Strategy for Operating in Cyberspace, Invitrogen, Office of Inspector General, U.S. Department of Health and Human Services, Plastic, City, Laboratory, HHS, Patheon, SUT, Applied Biosystems, Management, Fine chemical

WALTHAM, Mass., Nov. 12,2021 /PRNewswire/ --Thermo Fisher Scientific Inc., the world leader in serving science, today announced it will build a state-of-the-art manufacturing facility in Mebane, N.C.

Key Points: 
  • WALTHAM, Mass., Nov. 12,2021 /PRNewswire/ --Thermo Fisher Scientific Inc., the world leader in serving science, today announced it will build a state-of-the-art manufacturing facility in Mebane, N.C.
  • "The new manufacturing facility will help the U.S. meet future demand surges for vital laboratory products while bringing more high-quality jobs to North Carolina," said Mark Stevenson, executive vice president and chief operating officer, Thermo Fisher Scientific.
  • "We are pleased to welcome Thermo Fisher Scientific to the community and look forward to seeing their project come to fruition."
  • Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $35 billion.

New IVD System Enables Assay Developers and Clinical Laboratories to Accelerate Molecular Diagnostics Growth

Retrieved on: 
Tuesday, November 9, 2021
Efficiency, Science, Real-time, Mindful Scientific Inc., Fisher Scientific, West Pharmaceutical Services explosion, IVD, Thermo Fisher Scientific, Food, Research, Invitrogen, Regulation of tobacco by the U.S. Food and Drug Administration, Laboratory, Patheon, Risk, FDA, Applied Biosystems, Medical device

CARLSBAD, Calif., Nov. 9, 2021 /PRNewswire/ --As assay developers and clinical testing laboratories consider next steps for molecular diagnostics post-pandemic, a new in vitro diagnostic (IVD) system from Thermo Fisher Scientific will enable them to expand their assay menus and IVD testing capabilities moving forward.

Key Points: 
  • CARLSBAD, Calif., Nov. 9, 2021 /PRNewswire/ --As assay developers and clinical testing laboratories consider next steps for molecular diagnostics post-pandemic, a new in vitro diagnostic (IVD) system from Thermo Fisher Scientific will enable them to expand their assay menus and IVD testing capabilities moving forward.
  • The Applied Biosystems QuantStudio 7 Pro Dx Real-Time PCR System is a compact instrumentthat easily transitions from development to validation for maximum productivity.
  • The system's software comes with preconfigured run, analysis and report settings to reduce the risk of manual errors and improve efficiency.
  • "qPCR is an essential tool for clinical testing laboratories, and we have seen its importance for monitoring and managing the pandemic.

Oncocyte Announces the Clinical Launch of DetermaIO Immunotherapy Response Prediction Test

Retrieved on: 
Thursday, November 4, 2021
Lung, Accounting, Immunotherapy, Diagnosis, NSCLC, Cancer, Goal, Failure, Certification, Medical director, Surgeon, Neoplasm, Monroe Dunaway Anderson, Patient, West Pharmaceutical Services explosion, TIME, ESMO, Breast, SEC, Journal of Thoracic Oncology, Forward-looking statement, Maintenance, Company, TMB, Congress, Medicare, Biomarker, American Association for Cancer Research, COVID-19, Physiology, AACR, European Society for Medical Oncology, Oncology, Lung cancer, American Society of Clinical Oncology, Nasdaq, American Association, U.S. Securities and Exchange Commission, Publication, OCX, Intellectual property, GLOBE, ICI, Toxicity, Tumor microenvironment, Physician, ASCO, Medical imaging

IRVINE, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics and monitoring company with the mission to improve patient outcomes by providing clear insights that inform critical decisions in the diagnosis, treatment, and monitoring of cancer, today announced the clinical launch of its DetermaIOTM test. DetermaIO is a proprietary gene expression test that assesses the tumor immune microenvironment (TIME) to predict response to immunotherapy. In multiple clinical studies evaluating hundreds of patients across multiple tumor types, including lung, breast, bladder and renal cancers, the test has demonstrated the ability to predict response to immune checkpoint inhibitors (ICI) which has the potential to help inform the optimal use of immunotherapy treatment for more than one million eligible patients annually in the United States alone.

Key Points: 
  • DetermaIO is a proprietary gene expression test that assesses the tumor immune microenvironment (TIME) to predict response to immunotherapy.
  • I am impressed with the DetermaIO data, especially the superior progression free survival relative to legacy biomarkers and feel confident it will enable us to better navigate the immunotherapy decision.
  • The launch of DetermaIO is built on the growing body of evidence on the clinical applications of the test, suggesting a potential pan-cancer and pan-immunotherapy utility in both primary and metastatic settings.
  • DetermaIO, a gene expression test currently used as a research-use only tool, assesses the tumor microenvironment to predict response to immunotherapies.

NoviSystems Launches Data Analytics Solution for More Efficient Drug Manufacturing

Retrieved on: 
Monday, November 1, 2021
Shift, Death, Weakness, Thermo Fisher Scientific, QC, Compliance, 2021 Essex County Council election, Technology, Biotechnology, Hospital, Natural language processing, Wyeth, NextGen Healthcare, Pfizer, CAPA, Patient, Machine learning, Food, Biopharma LLC, West Pharmaceutical Services explosion, Medicine, Life, Software, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Degenerative disease, Biogen, Solution, Data science, Institute, IBM, QA, North Carolina State University, Fine chemical, Medical device, Management, Audit

An analytics solution for improving operational performance at BioPharma manufacturing facilities.

Key Points: 
  • An analytics solution for improving operational performance at BioPharma manufacturing facilities.
  • "Fusion Analytics for Quality Systems leverages a platform that can meet evolving needs in deviation, process and release analytics, leading to further improvements in operational performance."
  • Fusion Analytics for Quality Systems is a targeted application of NoviSystems' Fusion Analytics platform, an integrated software and hardware solution based on IBM's Power9 and Open Shift architectures.
  • Data fusion (unifying multiple text and numeric data sources), natural language processing and machine learning can integrate process development, continuous and batch manufacturing, and quality oversight.

Thermo Fisher Scientific Launches New Mass Spectrometry and Chromatography Solutions at ASMS 2021

Retrieved on: 
Monday, November 1, 2021
Science, Food safety, Proteomics, Thermo Fisher Scientific, QC, Research, Peptide, Industry, Knowledge, Workflow, TMO, Organization, Partnership, Database, Pennsylvania Convention Center, West Pharmaceutical Services explosion, NYSE, Invitrogen, Applied Biosystems, MAM, Mass spectrometry, American Society for Mass Spectrometry, Mindful Scientific Inc., Conference, Software, ASMS, Maintenance, Protein, Patheon, Metabolomics, Laboratory, Artificial intelligence, Acquisition, Fisher Scientific, Therapy, Society, Fine chemical, Medical imaging

PHILADELPHIA, Nov. 1, 2021 /PRNewswire/ --ASMS 2021 Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, is empowering scientists to drive groundbreaking discoveries with the introduction of new-generation mass spectrometry instruments, workflows and software.

Key Points: 
  • PHILADELPHIA, Nov. 1, 2021 /PRNewswire/ --ASMS 2021 Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, is empowering scientists to drive groundbreaking discoveries with the introduction of new-generation mass spectrometry instruments, workflows and software.
  • The company will showcase new additions to its industry-leading offering during the 69th American Society for Mass Spectrometry (ASMS) Conference on Mass Spectrometry and Allied Topics, being held October 31-November 4, in the Pennsylvania Convention Center, Philadelphia, Pennsylvania.
  • The Thermo Scientific Orbitrap Exploris MX mass detector allows biopharmaceutical laboratories to easily implement multi-attribute method (MAM), and performintact analysis of monoclonal antibodies, oligonucleotide mass determination and peptide mapping.
  • Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $35 billion.

Innovative Approach Redefines Data Analysis in Proteomics Research

Retrieved on: 
Monday, November 1, 2021
Science, Proteomics, Research, Peptide, Mass spectrometry, TMT, Deep learning, Algorithm, Pennsylvania Convention Center, West Pharmaceutical Services explosion, UHPLC, Invitrogen, Applied Biosystems, Thermo Fisher Scientific, American Society for Mass Spectrometry, Intelligence, CID, Chromatography, Mindful Scientific Inc., Conference, ASMS, Patheon, Laboratory, Artificial intelligence, Acquisition, Fisher Scientific, Data analysis, Proteome, Society, AI, Medical device, Fine chemical

Thermo Scientific Proteome Discoverer 3.0 software with CHIMERYS by MSAID leverages artificial intelligence (AI) to substantially enhance the identification rate and number of unique peptide identifications in proteomics data.

Key Points: 
  • Thermo Scientific Proteome Discoverer 3.0 software with CHIMERYS by MSAID leverages artificial intelligence (AI) to substantially enhance the identification rate and number of unique peptide identifications in proteomics data.
  • This innovative approach provides a 1.8-fold increase in the number of unique peptide identifications and a 1.5-fold increase in the number of protein identifications for typical proteomics data sets when compared to existing tools.In addition toimproved protein coverage and quantitation capabilities, Proteome Discoverer 3.0 software paired with CHIMERYS also facilitates faster data acquisition for increased sample throughput.
  • "By using Proteome Discoverer 3.0 software and CHIMERYS, scientists can now leverage AI for deeper mining of proteomic data.
  • This not only improves proteomic coverage, but also expands the ways in which proteomics scientists can acquire and apply their data."

Updated Software Solutions Enable New Insights and Productivity

Retrieved on: 
Monday, November 1, 2021
Science, Food safety, Proteomics, Lipid, Peptide, American Society for Mass Spectrometry, Technology, Research, Mass spectrometry, Compound, Deep learning, Pennsylvania Convention Center, West Pharmaceutical Services explosion, Artificial intelligence, Invitrogen, Applied Biosystems, Biopharma LLC, Mindful Scientific Inc., Chromatography, Conference, Software, ASMS, Patheon, Metabolomics, Environment, Laboratory, Fisher Scientific, Comet, MSN, Society, Medical device

The latest updates to the software solutions bring new features that enable researchers to achieve more high-quality results from their data with increased ease of use and performance.

Key Points: 
  • The latest updates to the software solutions bring new features that enable researchers to achieve more high-quality results from their data with increased ease of use and performance.
  • "Since hardware and software function hand-in-hand to produce increasingly accurate, but complex datasets, it is essential that we develop powerful software to expand analytical abilities and provide greater biological insights," said Mark Sander, senior director, software platform management, chromatography and mass spectrometry, Thermo Fisher Scientific.
  • Proteome Discoverer 3.0 software also includes an updated INFERYS prediction model, the Comet search engine, and a SureQuant method exporter node.
  • For more information on the latest software solutions from Thermo Fisher, please visit www.thermofisher.com/ASMS , or join us at ASMS 2021 from October 31to November 4, 2021.

Oncocyte to Report Third Quarter 2021 Financial Results on Tuesday, November 9th

Retrieved on: 
Tuesday, October 26, 2021
Accounting, Diagnosis, Cancer, Goal, Failure, Certification, Neoplasm, Patient, West Pharmaceutical Services explosion, Conference, Forward-looking statement, Maintenance, Company, Growth, COVID-19, Nasdaq, OCX, Intellectual property, GLOBE, Tumor microenvironment, Physician

The Company will host a conference call on Tuesday, November 9, 2021, at 4:30 pm ET / 1:30 pm PT to discuss the results along with recent corporate developments.

Key Points: 
  • The Company will host a conference call on Tuesday, November 9, 2021, at 4:30 pm ET / 1:30 pm PT to discuss the results along with recent corporate developments.
  • To access the live webcast, go to the investor relations section on the Companys website, or by clicking here: http://public.viavid.com/index.php?id=146378 .
  • The Companys tests are designed to help provide clarity and confidence to physicians and their patients at every stage.
  • DetermaRx identifies early-stage lung cancer patients who are at high risk for cancer recurrence and who may benefit from adjuvant chemotherapy.